EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease

Yu Kyung Jun iD, Yonghoon Choi iD, Cheol Min Shin iD, Young Soo Park iD, Nayoung Kim iD, Dong Ho Lee iD, Sung Wook Hwang iD, Hyuk Yoon iD

Gut and Liver · 2026

DOI: 10.5009/gnl250188 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Gut and Liver, 2026. Verfasst von Yu Kyung Jun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, Drug Substitution. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsAntibodies, Monoclonal, HumanizedInflammatory Bowel DiseasesDrug SubstitutionCrohn DiseaseColitis, UlcerativeHumansMaleFemaleRetrospective StudiesAdultRepublic of KoreaMiddle AgedInjections, SubcutaneousTreatment OutcomeAdministration, Intravenous

Stichwörter der Autor:innen

Crohn diseaseInflammatory bowel diseaseSubcutaneous applicationUlcerative colitisVedolizumab

Substanzen

vedolizumabGastrointestinal AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

ORCID-Profile: Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon

Zitieren

APA

Jun, Y. K., Choi, Y., Shin, C. M., Park, Y. S., Kim, N., Lee, D. H., Hwang, S. W., & Yoon, H. (2026). Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. Gut and Liver. https://doi.org/10.5009/gnl250188

Vancouver

Jun YK, Choi Y, Shin CM, Park YS, Kim N, Lee DH, et al. Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. Gut and Liver. 2026. doi:10.5009/gnl250188

BibTeX
@article{Jun2026,
  author = {Jun, Yu Kyung and Choi, Yonghoon and Shin, Cheol Min and Park, Young Soo and Kim, Nayoung and Lee, Dong Ho and Hwang, Sung Wook and Yoon, Hyuk},
  title = {Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease},
  journal = {Gut and Liver},
  year = {2026},
  doi = {10.5009/gnl250188}
}
Kostenlos starten →